These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade. Lin CC, Wu YT, Yang WC, Tsai MJ, Liu JS, Yang CY, Li SY, Ou SM, Tarng DC, Hsu CC. PLoS One; 2017; 12(12):e0189126. PubMed ID: 29216260 [Abstract] [Full Text] [Related]
7. Inhibition of the renin-angiotensin-aldosterone system: how to obtain this. Pende A, Montecucco F. Curr Pharm Des; 2012 Apr 23; 18(7):950-1. PubMed ID: 22283769 [No Abstract] [Full Text] [Related]
8. The Use of Renin-Angiotensin System Inhibitors in Patients With Chronic Kidney Disease. Leon SJ, Tangri N. Can J Cardiol; 2019 Sep 23; 35(9):1220-1227. PubMed ID: 31472818 [Abstract] [Full Text] [Related]
11. Renalism with Renin Angiotensin Aldosterone System Blockade: What Is the Consensus in Advanced Chronic Kidney Disease? Turino Miranda K, Ahmed SB. Can J Cardiol; 2024 Sep 23; 40(9):1729-1731. PubMed ID: 38777038 [No Abstract] [Full Text] [Related]
12. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use and renal outcomes: prevalent user designs may overestimate benefit. Tomlinson L, Smeeth L. JAMA Intern Med; 2014 Oct 23; 174(10):1706. PubMed ID: 25285737 [No Abstract] [Full Text] [Related]
14. How should we modify recommended renin-angiotensin-aldosterone system inhibition when facing the cardiorenal syndrome? Sexton DJ. Circ Heart Fail; 2014 May 23; 7(3):536. PubMed ID: 24847129 [No Abstract] [Full Text] [Related]
15. An ACE in the hole for patients with advanced chronic kidney disease? Park M, Hsu CY. JAMA Intern Med; 2014 Mar 23; 174(3):355-6. PubMed ID: 24342932 [No Abstract] [Full Text] [Related]
16. Renin-angiotensin system blockade in patients with chronic kidney disease: benefits, problems in everyday clinical use, and open questions for advanced renal dysfunction. Loutradis C, Price A, Ferro CJ, Sarafidis P. J Hum Hypertens; 2021 Jun 23; 35(6):499-509. PubMed ID: 33654237 [Abstract] [Full Text] [Related]
17. Combined Angiotensin Inhibition for CKD: The Truth Is Rarely Pure and Never Simple. Srivastava A, Schmidt IM, Palsson R. Am J Kidney Dis; 2024 Feb 23; 83(2):130-132. PubMed ID: 38069999 [No Abstract] [Full Text] [Related]
18. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade. Shenoy SV, Nagaraju SP, Bhojaraja MV, Prabhu RA, Rangaswamy D, Rao IR. Nephrology (Carlton); 2021 Nov 23; 26(11):858-871. PubMed ID: 34176194 [Abstract] [Full Text] [Related]
19. Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation? Sarafidis PA, Ruilope LM. Kidney Int; 2014 Mar 23; 85(3):536-46. PubMed ID: 24048382 [Abstract] [Full Text] [Related]
20. Blockers of the renin-angiotensin-aldosterone system: almost, but not yet, an absolute weapon against cardiovascular and renal diseases! Waeber B. J Renin Angiotensin Aldosterone Syst; 2012 Mar 23; 13(1):216. PubMed ID: 22389390 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]